Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Would You Pay ¥55,000 To See a Doctor From Your Tokyo Hotel?

Getting sick on vacation is never ideal. Getting sick in a country where you don’t speak the language, don’t know which clinic will take you and aren’t entirely sure how to get a prescription is considerably worse. A Doctor in 32 Languages, Delivered to Your Room As of September 1, there’s another option. Tokyo-based Mediphone […] The post Would You Pay ¥55,000 To See a Doctor From Your Tokyo…

International travelers visiting Japan face considerable challenges when they become ill, especially if they lack knowledge of the language, local clinics, and prescription processes. To address this issue, Tokyo-based companies Mediphone and Minakara, a subsidiary of NTT Docomo Group, have launched Online Doctor for tourists. The service allows visitors to receive medical care from the comfort of their hotel room for a fixed price of ¥55,000.

The package includes medical interpretation in 32 languages, a consultation with a Japanese doctor, online counseling on medication, and prescription-drug delivery. An alternative ¥45,000 plan offers a consultation and prescription, with patients collecting their medication from a nearby pharmacy. Despite the high cost, the service caters to a growing number of international visitors.

Japan welcomed a record 42.7 million international tourists in 2025, but navigating the country's medical system can be complicated for those without Japanese language skills or proper travel insurance. Roughly a quarter of inbound tourists carry no private medical insurance, and fewer than 1 in 20 have enrolled in Japan's travel insurance program.

Consequently, many travelers may face unpredictable and potentially substantial medical bills. While the ¥55,000 price tag may seem steep by Japanese standards, it may be more affordable for visitors accustomed to higher healthcare costs in their home countries, particularly if their insurance covers part of the bill. Hotel de Doctor 24 and Doctor to You also charge the same amount for similar services.

With tens of millions of visitors annually, the growing industry offers a convenient solution to a genuine problem, albeit at a considerable expense.

Written by urgent.news from Tokyo Weekender's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at tokyoweekender.com →

More in Health & Medicine

GC Wellbeing Partner Reports Successful Phase 3 Trial in China

A next-generation fat-dissolving drug candidate has reported positive results in a Phase 3 clinical trial in China, showing a significant reduction in submental fat after a single treatment cycle.GC…

  • Raziel Therapeutics' RZL-012 showed 30%+ higher response rate than placebo in China trial
  • Fosun Pharma and Raziel plan to file NDA with China's National Medical Products Administration
  • GC Wellbeing expects increased demand for body-contouring treatments after weight loss

Celltrion's Steqeyma Tops 16% U.S. Market Share

In the US ustekinumab market, Celltrion’s autoimmune disease treatment ‘Steqeyma’ exceeded a 16% market share in about a year since its launch.According to the pharmaceutical market research firm…

  • Celltrion's Steqeyma holds 16% U.S. market share in autoimmune disease treatment.
  • Steqeyma's market share grew by 6% in five months, from 10.2% in February to 16.2% in July.
  • Celltrion's localized sales strategy and insurance reimbursement contributed to Steqeyma's success.

CGBio, CGMedtech Host Spine Endoscopy Masterclass

Regenerative medicine specialist CGBio and spine and orthopedics specialist CGMedtech held the ‘2026 Spine Endoscopy Masterclass’ at the FIVE Labs Cadaver Lab in San Diego, California, the United…

  • CGBio and CGMedtech co-hosted Spine Endoscopy Masterclass on August 15 in San Diego.
  • 32 spine medical professionals from five Americas countries attended the event.
  • Workshop focused on UBE techniques with practical cadaver training led by Korean and US experts.

More from Thursday 3 September →